This piece of content is part of multiple stories. We recommend you read this content in the context of one of the following stories:
Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India
Author: Novartis, Published on: 1 April 2013
A decision issued today by the Indian Supreme Court regarding the Novartis breakthrough medicine Glivec® (imatinib mesylate) provides clarification on Indian patent law and discourages innovative drug discovery essential to advancing medical science for patients...
Related companies: Novartis